Global Aflibercept Biosimilars Competitive Landscape Professional Research Report 2025
Description
Global Aflibercept Biosimilars Competitive Landscape Professional Research Report 2025
Research Summary
Aflibercept biosimilars are biologic medical products highly similar to the original aflibercept (marketed as Eylea), which is an anti-VEGF (vascular endothelial growth factor) therapy used primarily to treat various retinal diseases, including age-related macular degeneration (AMD) and diabetic retinopathy. These biosimilars undergo rigorous testing to demonstrate their equivalence in terms of safety, efficacy, and quality to the reference product, providing more cost-effective treatment options while maintaining therapeutic benefits for patients suffering from serious eye conditions that can lead to vision loss.
According to DIResearch's in-depth investigation and research, the global Aflibercept Biosimilars market size was valued at XX Million USD in 2024 and is projected to reach XX Million USD by 2032, with a CAGR of XX% (2025-2032). Notably, the China market has changed rapidly in the past few years. By 2024, China's market size is expected to be XX Million USD, representing approximately XX% of the global market share. By 2032, it is anticipated to grow further to XX Million USD, contributing XX% to the worldwide market share.
The major global manufacturers of Aflibercept Biosimilars include Bayer, Roche, Regeneron, Sanofi, Novartis, Sartorius, Amgen, Samsung Bioepis, Mylan, Formycon, Coherus BioSciences, Cadila Pharmaceuticals, Hetero, Biocon, Gene Techno Science, Qilu Pharmaceutical etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Aflibercept Biosimilars. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Aflibercept Biosimilars market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Aflibercept Biosimilars market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Aflibercept Biosimilars industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Aflibercept Biosimilars Include:
Bayer
Roche
Regeneron
Sanofi
Novartis
Sartorius
Amgen
Samsung Bioepis
Mylan
Formycon
Coherus BioSciences
Cadila Pharmaceuticals
Hetero
Biocon
Gene Techno Science
Qilu Pharmaceutical
Aflibercept Biosimilars Product Segment Include:
Intravitreal Injection
Intravenous Injection
Aflibercept Biosimilars Product Application Include:
Wet Macular Degeneration
Metastatic Colorectal Cancer
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends
Chapter 2: Global Aflibercept Biosimilars Industry PESTEL Analysis
Chapter 3: Global Aflibercept Biosimilars Industry Porter’s Five Forces Analysis
Chapter 4: Global Aflibercept Biosimilars Major Regional Market Size (Revenue, Sales, Price) and Forecast Analysis
Chapter 5: Global Aflibercept Biosimilars Market Size and Forecast by Type and Application Analysis
Chapter 6: North America Aflibercept Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 7: Europe Aflibercept Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 8: China Aflibercept Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 9: APAC (Excl. China) Aflibercept Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 10: Latin America Aflibercept Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 11: Middle East and Africa Aflibercept Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 12: Global Aflibercept Biosimilars Competitive Analysis of Key Manufacturers (Sales, Revenue, Market Share, Price, Regional Distribution and Industry Concentration)
Chapter 13: Key Company Profiles (Product Portfolio, Sales, Revenue, Price and Gross Margin)
Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers
Chapter 15: Research Findings and Conclusion
Chapter 16: Methodology and Data Sources
Table of Contents
170 Pages
- 1 Aflibercept Biosimilars Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Aflibercept Biosimilars Product by Type
- 1.2.1 Intravitreal Injection
- 1.2.2 Intravenous Injection
- 1.3 Aflibercept Biosimilars Product by Application
- 1.3.1 Wet Macular Degeneration
- 1.3.2 Metastatic Colorectal Cancer
- 1.4 Global Aflibercept Biosimilars Market Revenue and Sales Analysis
- 1.4.1 Global Aflibercept Biosimilars Revenue Market Size Analysis (2020-2032)
- 1.4.2 Global Aflibercept Biosimilars Sales Market Size Analysis (2020-2032)
- 1.4.3 Global Aflibercept Biosimilars Market Sales Price Trend Analysis (2020-2032)
- 1.5 Aflibercept Biosimilars Industry Trends and Innovation
- 1.5.1 Aflibercept Biosimilars Industry Trends and Innovation
- 1.5.2 Aflibercept Biosimilars Market Drivers and Challenges
- 2 Aflibercept Biosimilars Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Aflibercept Biosimilars Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Aflibercept Biosimilars Market Analysis by Regions
- 4.1 Aflibercept Biosimilars Overall Market: 2024 VS 2025 VS 2032
- 4.2 Global Aflibercept Biosimilars Revenue and Forecast Analysis (2020-2032)
- 4.2.1 Global Aflibercept Biosimilars Revenue and Market Share by Region (2020-2025)
- 4.2.2 Global Aflibercept Biosimilars Revenue and Market Share Forecast by Region (2026-2032)
- 4.3 Global Aflibercept Biosimilars Sales and Forecast Analysis (2020-2032)
- 4.3.1 Global Aflibercept Biosimilars Sales and Market Share by Region (2020-2025)
- 4.3.2 Global Aflibercept Biosimilars Sales Forecast by Region (2026-2032)
- 4.4 Global Aflibercept Biosimilars Sales Price Trend Analysis (2020-2032)
- 5 Global Aflibercept Biosimilars Market Size by Type and Application
- 5.1 Global Aflibercept Biosimilars Market Size by Type
- 5.1.1 Global Aflibercept Biosimilars Revenue and Forecast Analysis by Type (2020-2032)
- 5.1.2 Global Aflibercept Biosimilars Sales and Forecast Analysis by Type (2020-2032)
- 5.2 Global Aflibercept Biosimilars Market Size by Application
- 5.2.1 Global Aflibercept Biosimilars Revenue and Forecast Analysis by Application (2020-2032)
- 5.2.2 Global Aflibercept Biosimilars Sales and Forecast Analysis by Application (2020-2032)
- 6 North America
- 6.1 North America Aflibercept Biosimilars Market Size and Growth Rate Analysis (2020-2032)
- 6.2 North America Key Manufacturers Analysis
- 6.3 North America Aflibercept Biosimilars Market Size by Type
- 6.3.1 North America Aflibercept Biosimilars Sales by Type (2020-2032)
- 6.3.2 North America Aflibercept Biosimilars Revenue by Type (2020-2032)
- 6.4 North America Aflibercept Biosimilars Market Size by Application
- 6.4.1 North America Aflibercept Biosimilars Sales by Application (2020-2032)
- 6.4.2 North America Aflibercept Biosimilars Revenue by Application (2020-2032)
- 6.5 North America Aflibercept Biosimilars Market Size by Country
- 6.5.1 US
- 6.5.2 Canada
- 7 Europe
- 7.1 Europe Aflibercept Biosimilars Market Size and Growth Rate Analysis (2020-2032)
- 7.2 Europe Key Manufacturers Analysis
- 7.3 Europe Aflibercept Biosimilars Market Size by Type
- 7.3.1 Europe Aflibercept Biosimilars Sales by Type (2020-2032)
- 7.3.2 Europe Aflibercept Biosimilars Revenue by Type (2020-2032)
- 7.4 Europe Aflibercept Biosimilars Market Size by Application
- 7.4.1 Europe Aflibercept Biosimilars Sales by Application (2020-2032)
- 7.4.2 Europe Aflibercept Biosimilars Revenue by Application (2020-2032)
- 7.5 Europe Aflibercept Biosimilars Market Size by Country
- 7.5.1 Germany
- 7.5.2 France
- 7.5.3 United Kingdom
- 7.5.4 Italy
- 7.5.5 Spain
- 7.5.6 Benelux
- 8 China
- 8.1 China Aflibercept Biosimilars Market Size and Growth Rate Analysis (2020-2032)
- 8.2 China Key Manufacturers Analysis
- 8.3 China Aflibercept Biosimilars Market Size by Type
- 8.3.1 China Aflibercept Biosimilars Sales by Type (2020-2032)
- 8.3.2 China Aflibercept Biosimilars Revenue by Type (2020-2032)
- 8.4 China Aflibercept Biosimilars Market Size by Application
- 8.4.1 China Aflibercept Biosimilars Sales by Application (2020-2032)
- 8.4.2 China Aflibercept Biosimilars Revenue by Application (2020-2032)
- 9 APAC (excl. China)
- 9.1 APAC (excl. China) Aflibercept Biosimilars Market Size and Growth Rate Analysis (2020-2032)
- 9.2 APAC (excl. China) Key Manufacturers Analysis
- 9.3 APAC (excl. China) Aflibercept Biosimilars Market Size by Type
- 9.3.1 APAC (excl. China) Aflibercept Biosimilars Sales by Type (2020-2032)
- 9.3.2 APAC (excl. China) Aflibercept Biosimilars Revenue by Type (2020-2032)
- 9.4 APAC (excl. China) Aflibercept Biosimilars Market Size by Application
- 9.4.1 APAC (excl. China) Aflibercept Biosimilars Sales by Application (2020-2032)
- 9.4.2 APAC (excl. China) Aflibercept Biosimilars Revenue by Application (2020-2032)
- 9.5 APAC (excl. China) Aflibercept Biosimilars Market Size by Country
- 9.5.1 Japan
- 9.5.2 South Korea
- 9.5.3 India
- 9.5.4 Australia
- 9.5.5 Southeast Asia
- 10 Latin America
- 10.1 Latin America Aflibercept Biosimilars Market Size and Growth Rate Analysis (2020-2032)
- 10.2 Latin America Key Manufacturers Analysis
- 10.3 Latin America Aflibercept Biosimilars Market Size by Type
- 10.3.1 Latin America Aflibercept Biosimilars Sales by Type (2020-2032)
- 10.3.2 Latin America Aflibercept Biosimilars Revenue by Type (2020-2032)
- 10.4 Latin America Aflibercept Biosimilars Market Size by Application
- 10.4.1 Latin America Aflibercept Biosimilars Sales by Application (2020-2032)
- 10.4.2 Latin America Aflibercept Biosimilars Revenue by Application (2020-2032)
- 10.5 Latin America Aflibercept Biosimilars Market Size by Country
- 10.6 Latin America Aflibercept Biosimilars Market Size by Country
- 10.6.1 Mexico
- 10.6.2 Brazil
- 11 Middle East & Africa
- 11.1 Middle East & Africa Aflibercept Biosimilars Market Size and Growth Rate Analysis (2020-2032)
- 11.2 Middle East & Africa Key Manufacturers Analysis
- 11.3 Middle East & Africa Aflibercept Biosimilars Market Size by Type
- 11.3.1 Middle East & Africa Aflibercept Biosimilars Sales by Type (2020-2032)
- 11.3.2 Middle East & Africa Aflibercept Biosimilars Revenue by Type (2020-2032)
- 11.4 Middle East & Africa Aflibercept Biosimilars Market Size by Application
- 11.4.1 Middle East & Africa Aflibercept Biosimilars Sales by Application (2020-2032)
- 11.4.2 Middle East & Africa Aflibercept Biosimilars Revenue by Application (2020-2032)
- 11.5 Middle East Aflibercept Biosimilars Market Size by Country
- 11.5.1 Saudi Arabia
- 11.5.2 South Africa
- 12 Competition by Manufacturers
- 12.1 Global Aflibercept Biosimilars Market Sales, Revenue and Price by Key Manufacturers (2021-2025)
- 12.1.1 Global Aflibercept Biosimilars Market Sales by Key Manufacturers (2021-2025)
- 12.1.2 Global Aflibercept Biosimilars Market Revenue by Key Manufacturers (2021-2025)
- 12.1.3 Global Aflibercept Biosimilars Average Sales Price by Manufacturers (2021-2025)
- 12.2 Aflibercept Biosimilars Competitive Landscape Analysis and Market Dynamic
- 12.2.1 Aflibercept Biosimilars Competitive Landscape Analysis
- 12.2.2 Global Key Manufacturers Headquarter Location and Key Area Sales
- 12.2.3 Market Dynamic
- 13 Key Companies Analysis
- 13.1 Bayer
- 13.1.1 Bayer Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.1.2 Bayer Aflibercept Biosimilars Product Portfolio
- 13.1.3 Bayer Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.2 Roche
- 13.2.1 Roche Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.2.2 Roche Aflibercept Biosimilars Product Portfolio
- 13.2.3 Roche Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.3 Regeneron
- 13.3.1 Regeneron Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.3.2 Regeneron Aflibercept Biosimilars Product Portfolio
- 13.3.3 Regeneron Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.4 Sanofi
- 13.4.1 Sanofi Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.4.2 Sanofi Aflibercept Biosimilars Product Portfolio
- 13.4.3 Sanofi Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.5 Novartis
- 13.5.1 Novartis Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.5.2 Novartis Aflibercept Biosimilars Product Portfolio
- 13.5.3 Novartis Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.6 Sartorius
- 13.6.1 Sartorius Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.6.2 Sartorius Aflibercept Biosimilars Product Portfolio
- 13.6.3 Sartorius Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.7 Amgen
- 13.7.1 Amgen Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.7.2 Amgen Aflibercept Biosimilars Product Portfolio
- 13.7.3 Amgen Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.8 Samsung Bioepis
- 13.8.1 Samsung Bioepis Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.8.2 Samsung Bioepis Aflibercept Biosimilars Product Portfolio
- 13.8.3 Samsung Bioepis Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.9 Mylan
- 13.9.1 Mylan Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.9.2 Mylan Aflibercept Biosimilars Product Portfolio
- 13.9.3 Mylan Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.10 Formycon
- 13.10.1 Formycon Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.10.2 Formycon Aflibercept Biosimilars Product Portfolio
- 13.10.3 Formycon Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.11 Coherus BioSciences
- 13.11.1 Coherus BioSciences Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.11.2 Coherus BioSciences Aflibercept Biosimilars Product Portfolio
- 13.11.3 Coherus BioSciences Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.12 Cadila Pharmaceuticals
- 13.12.1 Cadila Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.12.2 Cadila Pharmaceuticals Aflibercept Biosimilars Product Portfolio
- 13.12.3 Cadila Pharmaceuticals Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.13 Hetero
- 13.13.1 Hetero Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.13.2 Hetero Aflibercept Biosimilars Product Portfolio
- 13.13.3 Hetero Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.14 Biocon
- 13.14.1 Biocon Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.14.2 Biocon Aflibercept Biosimilars Product Portfolio
- 13.14.3 Biocon Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.15 Gene Techno Science
- 13.15.1 Gene Techno Science Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.15.2 Gene Techno Science Aflibercept Biosimilars Product Portfolio
- 13.15.3 Gene Techno Science Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 13.16 Qilu Pharmaceutical
- 13.16.1 Qilu Pharmaceutical Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.16.2 Qilu Pharmaceutical Aflibercept Biosimilars Product Portfolio
- 13.16.3 Qilu Pharmaceutical Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 14 Industry Chain Analysis
- 14.1 Aflibercept Biosimilars Industry Chain Analysis
- 14.2 Aflibercept Biosimilars Industry Raw Material and Suppliers Analysis
- 14.2.1 Aflibercept Biosimilars Key Raw Material Supply Analysis
- 14.2.2 Raw Material Suppliers and Contact Information
- 14.3 Aflibercept Biosimilars Typical Downstream Customers
- 14.4 Aflibercept Biosimilars Sales Channel Analysis
- 15 Research Findings and Conclusion
- 16 Methodology and Data Source
- 16.1 Methodology/Research Approach
- 16.2 Research Scope
- 16.3 Benchmarks and Assumptions
- 16.4 Date Source
- 16.4.1 Primary Sources
- 16.4.2 Secondary Sources
- 16.5 Data Cross Validation
- 16.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
